Catalog No.
DHD80906
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28908
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SGN-30, SGN 30, SGN30
Clone ID
SGN-30
Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281
Lymphomatoid Papulosis and Other Lymphoma-Like Diseases., PMID:31466587
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas., PMID:30231561
Antibody-Based Treatment of Acute Myeloid Leukemia., PMID:27734262
Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies., PMID:27592544
Roles of Bcl-2 and caspase-9 and -3 in CD30-induced human eosinophil apoptosis., PMID:26254825
Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy., PMID:24870054
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism., PMID:20423913
Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo., PMID:19799612
A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders., PMID:19789316
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma., PMID:19466965
SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies., PMID:19012503
Newer monoclonal antibodies for hematological malignancies., PMID:18565392
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies., PMID:18079362
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30., PMID:17909075
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma., PMID:17335294
Gateways to clinical trials., PMID:16810345
SGN-30 (Seattle genetics)., PMID:16610770
Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics., PMID:16049514
Gateways to clinical trials., PMID:15538546
Gateways to clinical trials. March 2003., PMID:12731460
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease., PMID:12097283
For research use only. Not for human or drug use.
